WebbRainier Therapeutics was developing a monoclonal antibody for the treatment of genetic orphan and oncology diseases. Development programs included achondroplasia, a rare skeletal condition, and metastatic bladder cancer patients who already have failed first-line chemotherapy. Rainier was acquired by Fusion Pharmaceuticals in 2024. WebbPrior to joining Rainier, Mr. Myers served as CEO, President and as a director of Cascadian Therapeutics Inc. prior to its acquisition by SeaGen in March of 2024. Mr. Myers also served as CEO of Aerocrine AB, a …

Rainier Therapeutics Company Profile: Valuation & Investors

Webb27 nov. 2024 · Rainier Therapeutics, Inc. is a privately-held, clinical stage biotechnology company developing a targeted biologic for the potential treatment of metastatic and early stage bladder cancer, an ... Webb10 mars 2024 · This ASSET PURCHASE AGREEMENT (this “Agreement”), dated as of March 10, 2024, is by and among FUSION PHARMACEUTICALS INC., a Canadian federal corporation (“Purchaser”), RAINIER THERAPEUTICS, INC., a Delaware corporation (“Seller”) and FORTIS ADVISORS LLC, a Delaware limited liability company, solely in its capacity as … hok elanto avoimet työpaikat helsinki

ReCode Therapeutics Presents New Preclinical Data from mRNA …

WebbSimply choose from a wide variety of templates and add them to your projects to get started instantly! Taskade is a supercharged productivity app that both individuals and … Webb15 feb. 2024 · Rainier Therapeutics, Inc. is a privately-held, clinical stage biotechnology company developing a targeted biologic for the potential treatment of metastatic bladder cancer. The company's antibody, vofatamab (formerly B-701), is focused specifically on the fibroblast growth factor receptor 3 (FGFR3), a known driver of bladder and other cancers. Webb4 juni 2014 · Description. Developer of cancer therapeutics technology intended to offer advanced targeted therapy for bladder cancer. The company's technology uses … hok elanto hautauspalvelut